Genetic Basis and Diagnosis of Platelet Disorders

Platelet disorders encompass a spectrum of inherited and acquired conditions in which the number, size or function of platelets is abnormal. The genetic basis of inherited platelet disorders ranges from monogenic defects affecting key components of thrombopoiesis and platelet granule biogenesis to complex multigenic contributors influencing platelet adhesion and signalling. Quantitative disorders, such as inherited thrombocytopenias, often result from mutations in genes governing megakaryocyte differentiation or proplatelet formation, whereas qualitative disorders arise from variants in genes encoding platelet surface receptors, cytoskeletal proteins or signalling molecules. Modern diagnosis integrates clinical evaluation of bleeding phenotype with haematological parameters, morphological assessment of platelet size and granule content, functional tests (aggregometry, flow cytometry and immunofluorescence microscopy) and molecular analysis. The advent of high-throughput sequencing has revolutionised the genetic characterisation of platelet disorders, enabling comprehensive screening of known and novel candidate genes. Improved genotype–phenotype correlations now inform personalised management strategies, including targeted therapies and genetic counselling. The global significance of this field lies in its impact on patient care, from early recognition of life-threatening bleeding syndromes to the development of novel treatment modalities such as thrombopoietin receptor agonists and, in rare cases, haematopoietic stem cell transplantation.

Research from Nature Portfolio

Recent studies have elucidated the role of the NBEAL2 protein in grey platelet syndrome, a macro-thrombocytopenia characterised by α-granule deficiency and bleeding tendency. By mapping the interactome of NBEAL2 in primary T cells, researchers identified a direct association with CTLA-4, uncovering a novel mechanism linking granule biogenesis to immune regulation. Loss of NBEAL2 not only disrupts platelet α-granule formation but also leads to reduced CTLA-4 expression in conventional T cells, offering a rationale for immunoglobulin-based therapies in patients exhibiting concomitant autoimmunity. This work highlights the unexpected interplay between platelet-specific proteins and immune checkpoints, thereby expanding the pathophysiological framework of inherited platelet disorders.

Genetic Basis and Diagnosis of Platelet Disorders publication trend

The graph below shows the total number of articles in genetic basis and diagnosis of platelet disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Megakaryocyte: Large bone marrow precursor cell that gives rise to platelets through cytoplasmic fragmentation.

Proplatelet formation: The process by which cytoplasmic extensions from megakaryocytes fragment into circulating platelets.

Thrombopoietin receptor agonist: A therapeutic agent that stimulates platelet production by activating the thrombopoietin receptor on megakaryocytes.

Aggregometry: A laboratory technique measuring the ability of platelets to clump together in response to agonists, used to assess function.

High-throughput sequencing: Rapid DNA sequencing methods that allow simultaneous analysis of multiple genes or entire exomes/genomes.

References

1. NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells. Nature Communications (2023).
2. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica (2016).
3. Inherited Platelet Disorders: An Updated Overview. International Journal of Molecular Sciences (2021).
4. Use of next‐generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. Journal of Thrombosis and Haemostasis (2015).